SEC 8-K filings with transcript text
Aug 12, 2016
8-K 1 f8k081116_soligenix.htm
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 11, 2016
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
29 Emmons Drive,
Suite C-10
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On August 11, 2016, Soligenix, Inc. (the “Company”) issued a press release announcing its results of operations for the second quarter ended June 30, 2016. A copy of the press release is attached as Exhibit 99.1 to this report.
The information in this report, including the exhibit hereto, is being “furnished” in accordance with General Instruction B.2 of Form 8-K. As such, this information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filings with the Securities and Exchange Commission unless it is explicitly so incorporated in such filings.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Title
99.1
Press release issued by the Company on August 11, 2016.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Soligenix, Inc.
August 11, 2016 By: /s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Aug 21, 2013
8-K 1 f8k081213_soligenix.htm
f8k081213_soligenix.htm
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 12, 2013
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
29 Emmons Drive,
Suite C-10
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On August 12, 2013, Soligenix, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended June 30, 2013. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Title
99.1
Press release issued by the Company on August 12, 2013.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Soligenix, Inc.
By:
/s/ Christopher J. Schaber
August 21, 2013
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Exhibit No.
Title
99.1
Press release issued by the Company on August 12, 2013.
May 8, 2013
8-K 1 f8k050313_soligenix.htm
f8k050313_soligenix.htm
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 3, 2012
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
29 Emmons Drive,
Suite C-10
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On May 3, 2013, Soligenix, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended March 31, 2013. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Title
99.1
Press release issued by the Company on May 3, 2013.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Soligenix, Inc.
By: /s/ Christopher J. Schaber
May 8, 2013
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Exhibit No.
Title
99.1
Press release issued by the Company on May 3, 2013.
Aug 10, 2012
8-K 1 f8k081012_soligenix.htm
f8k081012_soligenix.htm
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 10, 2012
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
29 Emmons Drive,
Suite C-10
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On August 10, 2012, Soligenix, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended June 30, 2012. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Title
99.1
Press release issued by the Company on August 10, 2012.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Soligenix, Inc.
August 10, 2012 By: /s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Exhibit No.
Description
99.1
Press release issued by the Company on August 10, 2012.
May 15, 2012
8-K 1 f8k051412_soligenix.htm
f8k051412_soligenix.htm
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 14, 2012
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
29 Emmons Drive,
Suite C-10
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On May 14, 2012, Soligenix, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended March 31, 2012. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Title
99.1
Press release issued by the Company on May 14, 2012.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Soligenix, Inc.
May 15, 2012
By:
/s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Exhibit No.
Title
99.1
Press release issued by the Company on May 14, 2012.
Aug 12, 2011
8-K 1 f8k081211_soligenix.htm
f8k081211_soligenix.htm
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 12, 2011
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
29 Emmons Drive,
Suite C-10
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On August 12, 2011, Soligenix, Inc. (the “Company”), a late-stage biopharmaceutical company, issued a press release announcing its results of operations for the quarter ended June 30, 2011. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Title
99.1
Press release issued by the Company on August 12, 2011.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
August 12, 2011
Soligenix, Inc.
By: /s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Exhibit No.
Description
99.1
Press release issued by the Company on August 12, 2011.
May 13, 2011
8-K 1 f8k051311_soligenix.htm
f8k051311_soligenix.htm
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 13, 2011
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
29 Emmons Drive,
Suite C-10
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On May 13, 2011, Soligenix, Inc. (the “Company”), a late-stage biopharmaceutical company, issued a press release announcing its results of operations for the quarter ended March 31, 2011. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press release issued by the Company on May 13, 2011.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Soligenix, Inc.
May 13, 2011
by:
/s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Exhibit No.
Description
99.1
Press release issued by the Company on May 13, 2011.
Mar 29, 2011
8-K 1 f8k032911_soligenix.htm
f8k032911_soligenix.htm
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 29, 2011
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
29 Emmons Drive,
Suite C-10
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On March 29, 2011, Soligenix, Inc. (the “Company”), a late-stage biopharmaceutical company, issued a press release announcing its results of operations for the year ended December 31, 2010. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press release issued by the Company on March 29, 2011.
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Soligenix, Inc.
March 29, 2011
by:
/s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
3
Exhibit No.
Description
99.1
Press release issued by the Company on March 29, 2011.
4
Nov 16, 2010
8-K 1 f8k111210_soligenix.htm
f8k111210_soligenix.htm
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 12, 2010
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
29 Emmons Drive,
Suite C-10
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On November 12, 2010, Soligenix, Inc. (the “Company”), a late-stage biopharmaceutical company, issued a press release announcing its results of operations for the quarter ended September 30, 2010. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press release issued by the Company on November 12, 2010.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Soligenix, Inc.
November 16, 2010
By:
/s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Exhibit No.
Description
99.1
Press release issued by the Company on November 12, 2010.
Aug 13, 2010
8-K 1 f8k081310_soligenix.htm
f8k081310_soligenix.htm
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 13, 2010
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
29 Emmons Drive,
Suite C-10
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On August 13, 2010, Soligenix, Inc. (the Company), a late-stage biopharmaceutical company, issued a press release announcing its results of operations for the quarter ended June 30, 2010. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press release issued by the Company on August 13, 2010.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Soligenix, Inc.
August 13, 2010
By:
/s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Exhibit No.
Description
99.1
Press release issued by the Company on August 13, 2010.
May 17, 2010
8-K 1 f8k051710_soligenix.htm
f8k051710_soligenix.htm
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 17, 2010
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
29 Emmons Drive,
Suite C-10
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On May 17, 2010, Soligenix, Inc. (the Company), a late-stage biopharmaceutical company, issued a press release announcing its results of operations for the quarter ended March 31, 2010. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press release issued by the Company on May 17, 2010.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Soligenix, Inc.
May 17, 2010
By:
/s/Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Exhibit No.
Description
99.1
Press release issued by the Company on May 17, 2010.
Apr 1, 2010
8-K 1 f8k040110_soligenix.htm
f8k040110_soligenix.htm
Washington,
8-K
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): April 1, 2010
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
Employer Identification Number)
29 Emmons Drive,
Suite
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On April 1, 2010, Soligenix, Inc. (the Company), a late-stage biopharmaceutical company, issued a press release announcing its results of operations for the year ended December 31, 2009. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press release issued by the Company on April 1, 2010.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Soligenix, Inc.
April 1, 2010
by:
/s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Exhibit No.
Description
99.1
Press release issued by the Company on April 1, 2010.
Nov 13, 2009
8-K 1 form8k.htm
form8k.htm
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 13, 2009
Commission File No. 000-16929
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
29 Emmons Drive, Suite C-10
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On November 13, 2009, Soligenix, Inc. (the Company), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, issued a press release announcing its results of operations for the three and nine months ended September 30, 2009. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be "filed" for the purposes of Section 18 of the Securitites Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit No. Description
99.1 Press release issued by the Company on November 13, 2009.
- 2 -
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
November 13, 2009
by:
/s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
- 3 -
Exhibit No. Description
99.1 Press release issued by the Company on November 13, 2009.
- 4 -
Aug 14, 2009
8-K 1 form8k.htm
form8k.htm
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 14, 2009
Commission File No. 000-16929
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
29 Emmons Drive, Suite C-10
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On August 14, 2009, DOR BioPharma, Inc. (the “Company”) issued a press release announcing its results of operations for the three and six months ended June 30, 2009. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit No.Title
99.1 Press release issued by the Company on August 14, 2009.
- 2 -
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
August 14, 2009
by:
/s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
- 3 -
Exhibit No. Description
99.1 Press release issued by the Company on August 14, 2009.
- 4 -
May 15, 2009
8-K 1 dor8kpr1q09.htm
dor8kpr1q09.htm
Washington,
8-K
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 15, 2009
Commission File No. 000-16929
DOR
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
Employer Identification Number)
29 Emmons Drive,
Suite
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On May 15, 2009, DOR BioPharma, Inc. issued a press release announcing its results of operations for the quarter ended March 31, 2009. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit No. Title
99.1 Press release issued by DOR BioPharma, Inc. on May 15, 2009.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
May 15, 2009
by:
/s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Exhibit No. Description
99.1 Press release issued by DOR BioPharma, Inc. on May 15, 2009.
Mar 31, 2009
8-K 1 dor8kfinancial2008.htm
dor8kfinancial2008.htm
Washington,
8-K
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 31, 2009
Commission File No. 000-16929
DOR
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
Employer Identification Number)
29 Emmons Drive,
Suite
Princeton, NJ
08540
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On March 31, 2009, DOR BioPharma, Inc. issued a press release announcing its results of operations for the fiscal year ended December 31, 2008. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit No. Title
99.1 Press release issued by DOR BioPharma, Inc. on March 31, 2009.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DOR
March 31, 2009
by:
/s/ Christopher J. Schaber____________________
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Exhibit No. Description
99.1 Press release issued by DOR BioPharma, Inc. on March 31, 2009.
Nov 14, 2008
8-K 1 pr8k3q10q2008.htm
pr8k3q10q2008.htm
Washington,
8-K
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 14, 2008
Commission File No. 000-16929
DOR
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
Employer Identification Number)
850 Bear Tavern Road,
Suite 201
Ewing, NJ
08628
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On November 14, 2008, DOR BioPharma, Inc. issued a press release announcing its results of operations for the fiscal year ended September 30, 2008. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit No. Title
99.1 Press release issued by DOR BioPharma, Inc. on November 14, 2008.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DOR
November 14, 2008
by:
/s/Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Exhibit No. Description
99.1 Press release issued by DOR BioPharma, Inc. on November 14, 2008.
Aug 15, 2008
8-K 1 dor2q08financialpressrelease.htm
dor2q08financialpressrelease.htm
Washington,
8-K
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 15, 2008
Commission File No. 000-16929
DOR
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
Employer Identification Number)
850 Bear Tavern Road,
Suite 201
Ewing, NJ
08628
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On August 15, 2008, DOR BioPharma, Inc. issued a press release announcing its results of operations for the fiscal year ended June 30, 2008. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit No. Title
99.1 Press release issued by DOR BioPharma, Inc. on August 15, 2008.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DOR
August 15, 2008
by:
/s/Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Exhibit No. Description
99.1 Press release issued by DOR BioPharma, Inc. on August 15, 2008.
May 16, 2008
8-K 1 earnings8kfor1q2008.htm
earnings8kfor1q2008.htm
Washington,
8-K
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 16, 2008
Commission File No. 000-16929
DOR
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
Employer Identification Number)
850 Bear Tavern Road,
Suite 201
Ewing, NJ
08628
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On May 16, 2008, DOR BioPharma, Inc. issued a press release announcing its results of operations for the quarter ended March 31, 2008. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Title
99.1 Press release issued by DOR BioPharma, Inc. on May 16, 2008.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DOR
May 16, 2008
by:
/s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Exhibit No. Description
99.1 Press release issued by DOR BioPharma, Inc. on May 16, 2008.
Mar 27, 2008
8-K 1 earnings8kyear2007.htm
earnings8kyear2007.htm
Washington,
8-K
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 27, 2008
Commission File No. 000-16929
DOR
(Exact name of small business issuer as specified in its charter)
41-1505029
(State or other jurisdiction of incorporation or organization)
Employer Identification Number)
850 Bear Tavern Road,
Suite 201
Ewing, NJ
08628
(Address of principal executive offices)
(Zip Code)
(609) 538-8200
(Issuer’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On March 27, 2008, DOR BioPharma, Inc. issued a press release announcing its results of operations for the year ended December 31, 2007. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit No. Title
99.1 Press release issued by DOR BioPharma, Inc. on March 27, 2008.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DOR
March 27, 2008
by:
/s/ Christopher J. Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Exhibit No. Description
99.1 Press release issued by DOR BioPharma, Inc. on March 27, 2008.
This page provides Soligenix Inc. (SNGX) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on SNGX's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.